A 59-year-old cisgender man with HIV is seen in clinic for follow-up after several recent episodes of angina. Approximately 9 years ago, he was diagnosed with HIV and started on a regimen of dolutegravir-abacavir-lamivudine. He has tolerated this regimen well and consistently has suppressed HIV RNA levels. Based on his recent episodes of angina and concern for cardiovascular disease, the plan is to switch to a regimen that does not include abacavir. The clinician is considering using a two-drug regimen of dolutegravir-lamivudine. A baseline HIV drug resistance genotype prior to starting antiretroviral therapy showed no resistance mutations, and he has never had virologic failure. He is immune to hepatitis B virus.